Please use this identifier to cite or link to this item:
http://dx.doi.org/10.25673/57050
Title: | MEK inhibitors : novel targeted therapies of neurofibromatosis associated benign and malignant lesions |
Author(s): | Harder, Anja |
Issue Date: | 2021 |
Type: | Article |
Language: | English |
Abstract: | MAP/ERK kinase 1 and 2 (MEK 1/2) inhibitors (MEKi) are investigated in several trials to treat lesions that arise from pathogenic variants of the Neurofibromatosis type 1 and type 2 genes (NF1, NF2). These trials showed that MEKi are capable to shrink volume of low grade gliomas and plexiform neurofibromas in NF1. Targeting other lesions being associated with a high morbidity in NF1 seems to be promising. Due to involvement of multiple pathways in NF2 associated lesions as well as in malignant tumors, MEKi are also used in combination therapies. This review outlines the current state of MEKi application in neurofibromatosis and associated benign and malignant lesions. |
URI: | https://opendata.uni-halle.de//handle/1981185920/59001 http://dx.doi.org/10.25673/57050 |
Open Access: | Open access publication |
License: | (CC BY 4.0) Creative Commons Attribution 4.0 |
Sponsor/Funder: | Publikationsfonds MLU |
Journal Title: | Biomarker Research |
Publisher: | Biomed Central |
Publisher Place: | London |
Volume: | 9 |
Original Publication: | 10.1186/s40364-021-00281-0 |
Appears in Collections: | Open Access Publikationen der MLU |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s40364-021-00281-0.pdf | 1.49 MB | Adobe PDF | View/Open |